Cortex to Discuss AMPAKINE(R) Technology at the Windhover NeuroAlliances Partnering Conference.IRVINE, Calif. -- Cortex Pharmaceuticals, Inc.'s (AMEX AMEX See: American Stock Exchange : COR) Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. and Chief Scientific Officer, Dr. Mark A. Varney, will be presenting at the Windhover NeuroAlliances Partnering Conference to be held at the Western Peachtree Plaza Hotel, directly following the Annual Society for Neurosciences Meeting in Atlanta, GA. Dr. Varney's presentation is scheduled for Thursday, October 19, 2006 at 11:20 AM. Dr. Varney will provide an overview of Cortex's AMPAKINE[R] research program, including the Company's rationale for partnering its lead AMPAKINE, CX717 for the treatment of Attention Deficit Hyperactivity Disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. (ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or ). Cortex was invited to present based on its selection as one of the 'Ten Top Partnering Opportunities' in the neuroscience area. The selection of the top ten, from over 150 CNS-focused company candidates, was made by a selection committee comprised of NI Research, Windhover Information, and Easton Associates. The conference is designed to facilitate alliance-building discussions between those presenting companies and a wide range of pharmaceutical companies that will be in attendance. Dr. Varney will also provide an update on corporate partnering prospects and discuss the status of the Company's strategy to in-license late stage non-AMPAKINE central nervous system product candidates for potential use in "Orphan Drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the " indications. Such in-licensed products are being pursued to complement the activities underway with Cortex's AMPAKINE technology and to broaden the development pipeline for the Company. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/) Forward-Looking Statement Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under pre-clinical or clinical tests and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion